• Analyst Coverage
• Corporate Governance
• Email Alerts
• FAQ
• Financial Reports
• Fundamentals
• Image Library
• Information Request
• Investor Events
• SEC Filings
• Presentation Archive
• Press Releases
• Stock Chart
• Stock Quote
• Worth Noting

Current | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000

Applied Biosystems and Celera to Webcast Investor Meetings

Foster City, CA and Alameda, CA - March 05, 2008

Applied Biosystems Group (NYSE:ABI) and Celera Group (NYSE:CRA), Applera Corporation businesses, will webcast meetings with investors to be held at Applied Biosystems’ offices in Foster City, California on March 12, 2008. The Applied Biosystems meeting is scheduled to begin at 11:30 a.m. PT, during which Applied Biosystems president Mark Stevenson and other senior executives will provide an overview of the Applied Biosystems’ businesses and take questions from investors. The Celera meeting is scheduled to begin at 1:00 p.m. PT and end at 2:30 p.m. PT, during which Celera president Kathy Ordoñez will discuss Celera’s businesses and take investors’ questions.

Interested parties who wish to listen to the webcast should visit the “Investors & Media” section of either www.applera.com, www.appliedbiosystems.com, or www.celera.com. It is suggested that listeners access the live webcast 15 minutes before it is scheduled to begin. The webcast replay will be archived on the Presentations page of the Investors & Media section of each website.

About Applera Corporation
Applera Corporation consists of two operating groups. Applied Biosystems serves the life science industry and research community by developing and marketing instrument-based systems, consumables, software, and services. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to make scientific discoveries and develop new pharmaceuticals. Applied Biosystems’ products also serve the needs of some markets outside of life science research, which we refer to as “applied markets,” such as the fields of: human identity testing (forensic and paternity testing); biosecurity, which refers to products needed in response to the threat of biological terrorism and other malicious, accidental, and natural biological dangers; and quality and safety testing, such as testing required for food and pharmaceutical manufacturing. Applied Biosystems is headquartered in Foster City, CA, and reported sales of approximately $2.1 billion during fiscal 2007. The Celera Group is a diagnostics business delivering personalized disease management through a combination of products and services incorporating proprietary discoveries. Berkeley HeartLab, a subsidiary of Celera, offers services to predict cardiovascular disease risk and optimize patient management. Celera also commercializes a wide range of molecular diagnostic products through its strategic alliance with Abbott and has licensed other relevant diagnostic technologies developed to provide personalized disease management in cancer and liver diseases. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.applera.com, or by telephoning 800.762.6923. All information in this press release is as of the date of the release, and Applera does not undertake any duty to update this information unless required by law.

Copyright © 2008 Applera Corporation. All Rights Reserved. AB (Design), Applied Biosystems, Applera, and Celera are registered trademarks of Applera Corporation or its subsidiaries in the U.S. and/or certain other countries.

Notice To Readers: Celera's press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.